Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis.

Authors
Category Primary study
JournalMultiple sclerosis and related disorders
Year 2017
Rebound syndrome after medication is defined as flare-up disease activity upon withdrawal of treatment in patients with multiple sclerosis (MS). This phenomenon has particularly been shown for natalizumab in many previous reports. Similarly, a substantial amount of case reports have been published in the last four years suggesting that cessation of fingolimod treatment may also cause an increased frequency or severity of relapse in a subset of patients with MS
Epistemonikos ID: 2a92ce1a7d6b1152831ec4fd1f752efac56c7ff8
First added on: Oct 30, 2021